What We Do
Our mission is to ensure, by continually providing high standards of training and encouraging a high level of commitment from all of our employees, that PharSafer® provides quality Pharmacovigilance and Medical Services to our clients. The aim is by having such exacting standards that we can help protect patients from any untoward adverse events and risks, maximising patient benefits and minimising patient risk.
PharSafer® also strives to provide quality Medical Information Services to ensure that accurate and up to date information is provided promptly to Healthcare professionals and patients to ensure client medicines are used properly to ensure maximum patient benefit. As the product knowledge evolves so PharSafer® can help maintain the changes to product information to ensure the most current information is used when answering medical enquiries.
Setting the Industry Standards
To ensure that PharSafer® provides all clients with quality Pharmacovigilance and Medical Information Services, we are committed to employing only the best people and applying the highest standards to our training across the company. This means that we deliver only the best possible level of both quality and service to our Clients.
Experience in Sectors
PharSafer® is continually expanding its reach in terms of the number of countries in which it conducts Pharmacovigilance, Medical & Regulatory activities and provides support for client companies. All of our technical people have scientific, pharmacy, nursing or medical first degrees or higher and all receive thorough training in Pharmacovigilance and Medical Information when they join the Company. Training is also on-going, developmental and includes competency testing and refresher training both on processes and the complex global legislation. PharSafer® encourages learning via in-house training, external courses, conference attendance and Regulatory seminars.
PharSafer® News
PharSafer Summary of MHRA Pharmacovigilance Inspections Metrics Report
On the 26th February, the Medicines & Healthcare products Regulatory Agency (MHRA) released their latest update in series of guidance... read more →
March 24, 2021
Rolling-out, and rolling-up sleeves: The current COVID-19 situation; the threats for mass inoculation, and impact on drug safety
A brief overview of several vaccines that are entering the market, potentially available for inoculation by early-mid 2021. This article... read more →
December 1, 2020
FDA Guidance for Enhancing Diversity Populations in Clinical Trials
The United States Food and Drug Administration (FDA) have released their latest guidance for clinical trials, regarding the topic of enhancing the... read more →
November 13, 2020
MHRA Guidance for Brexit Transition Period
On the 1st September 2020, the Medicines & Healthcare products Regulatory Agency (MHRA) released a series of guidance documents for industry... read more →
September 17, 2020
MedDRA MSSO Webinar Summary – Upcoming Changes in Version 23.1
On the 26th August 2020, MedDRA MSSO hosted a webinar on the subject of changes made for the upcoming MedDRA version... read more →
August 27, 2020
FDA Annual PMR & PMC Report
The Food and Drug Administration (FDA) has published their report on the performance of industry organisations in fulfilling their drug... read more →
August 10, 2020
